Trial Profile
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Fosaprepitant (Primary) ; Dexamethasone; Ondansetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms PN031
- Sponsors Merck Sharp & Dohme
- 11 Apr 2019 This trial has been completed in Spain, according to European Clinical Trials Database.
- 01 Nov 2018 Results of post hoc analysis exploring factors that may have influenced response, published in the Supportive Care in Cancer.
- 09 Dec 2017 Results assessing efficacy, presented at the 40th Annual San Antonio Breast Cancer Symposium.